Skip to main content
SpringerLink
Log in

Cabergoline

A Review of its Efficacy in the Treatment of Parkinson’s Disease

  • Adis Drug Evaluation
  • Published:
CNS Drugs Aims and scope Submit manuscript

Summary

Abstract

The dopamine agonist cabergoline has been most widely studied as an adjuvant to levodopa/carbidopa therapy in patients with advanced Parkinson’s disease experiencing response fluctuations (‘wearing-off’ and ‘on-off’ phenomena) to long term levodopa therapy. Significant improvements in Unified Parkinson’s Disease Rating Scale (UPDRS) scores for motor function and activities of daily living were observed with cabergoline in a placebo-controlled study in this patient group. In addition, cabergoline significantly reduced ‘off’ time compared with placebo after 12 and 24 weeks’ therapy. The requirement for levodopa to control symptoms of Parkinson’s disease is reduced in patients given adjuvant cabergoline; however, the duration of this effect remains unclear. To date, adjuvant cabergoline has been shown to control the symptoms of advanced Parkinson’s disease for periods of up to 3 years in noncomparative studies.

Data indicate that cabergoline is at least as effective as bromocriptine in this patient group. Limited data indicate that it is more effective than pergolide in controlling certain disabilities associated with long term levodopa therapy (specifically nocturnal disabilities and motor function during the ‘off’ period).

In patients with early Parkinson’s disease, de novo therapy with cabergoline was associated with a significantly lower risk of developing motor complications after 5 years than de novo levodopa/carbidopa therapy in a single trial. The incidence of motor complications (≥1) in patients randomised to receive cabergoline (± levodopa/carbidopa as required) was 22.3 versus 33.7% in patients given only levodopa/carbidopa (p < 0.05). After 5 years, 64% of cabergoline recipients required additional levodopa/carbidopa; however, the dosage was significantly lower than that given to patients receiving only levodopa/carbidopa. UPDRS motor function scores were better in the levodopa/carbidopa group.

The tolerability profile of cabergoline appears typical of a dopamine agonist. CNS disturbances (including visual hallucinations, confusion, dizziness/light-headedness, increased libido, increased dyskinesias, insomnia and somnolence) and gastric upset are the most common events, but are rarely severe. Clinical trials indicate that the tolerability of cabergoline is similar to that of bromocriptine, but may be better than pergolide.

Conclusions: Cabergoline is useful for controlling symptoms in patients with advanced Parkinson’s disease experiencing response fluctuations to long term levodopa therapy. Importantly, it appears to be valuable as de novo therapy in patients with early disease in terms of reducing the risk of motor complications. Its long elimination half-life (63 to 68 hours) and long duration of action, which allow once daily administration, may prove advantageous in terms of attaining maximal symptom control.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Montastruc JL, Rascol O, Senard JM. Current status of dopamine agonists in Parkinson’s disease management. Drugs 1993 Sep; 46: 384–93

    Article  PubMed  CAS  Google Scholar 

  2. Obeso JA, Grandas F, Vaamonde J, et al. Motor complications associated with chronic levodopa therapy in Parkinson’s disease. Neurology 1989; 39 Suppl. 2: 11–9

    Google Scholar 

  3. Yahr MD. Parkinson’s disease: new approaches to diagnosis and treatment. Acta Neurol Scand 1993; 146: 22–5

    CAS  Google Scholar 

  4. Schelosky L, Poewe W. Current strategies in the drug treatment of advanced Parkinson’s disease — new modes of dopamine substitution. Acta Neurol Scand 1993; 87 Suppl. 146: 46–9

    CAS  Google Scholar 

  5. Schuh LA, Bennett JP. Suppression of dyskinesias in Parkinson’s disease: continuous intravenous levodopa shifts the dose-response for production of dyskinesias but not relief of parkisonism in patients with advanced Parkinson’s disease. Neurology 1993; 43: 1545–50

    Article  PubMed  CAS  Google Scholar 

  6. Stocchi F. Dopamine agonists in Parkinson’s disease: what is theirrole in early treatment? CNS Drugs 1998 Sep; 10: 159–70

    Article  CAS  Google Scholar 

  7. Poewe W. Adjuncts to levodopa therapy: dopamine agonists. Neurology 1998 Jun; 50 Suppl. 6: 23–6

    Article  Google Scholar 

  8. Ogawa N. Early introduction of dopamine agonists in the long-term treatment of Parkinson’s disease. Neurology 1998 Aug; 51 Suppl. 2: 13–20

    Article  Google Scholar 

  9. Durif F. Treating and preventing levodopa-induced dyskinesias: current and future strategies. Drugs Aging 1999 May; 14:337–45

    Article  PubMed  CAS  Google Scholar 

  10. Farmitalia Carlo Erba. Milan, Italy. (Data on file)

  11. Strolin Benedetti M, Dostert P, Barone D, et al. In vivo interaction of cabergoline with rat brain dopamine receptors labelled with [3H]N-n-propylnorapomorphine. Eur J Pharmacol 1990 Oct 23; 187:399–408

    Article  CAS  Google Scholar 

  12. Di Salle E, Ornati G, Briatico G. FCE 21336, a new ergoline derivative with a potent and long-acting lowering effect on prolactin secretion in rats. J Endocrinol Invest 1982; 5: 45

    Google Scholar 

  13. Di Salle E, Ornati G, Giuduci D, et al. Prolactin lowering effect of a new ergoline derivative, FCE 21336, in the rat: a comparison with bromocriptine. Acta Endocrinol 1983; 103: 265

    Google Scholar 

  14. Fariello RG, Carfagna N, Buonamici M, et al. Cabergoline: a long-acting D-2 agonist with antiparkinsonian properties -preclinical studies [abstract]. Ann Neurol 1991 Aug; 30: 258

    Google Scholar 

  15. Pontiroli AE, Viberti GC, Mangili R, et al. Selective and extremely long inhibition of prolactin release in man by 1-ethyl-3-(3′-dimethylaminopropyl)-3-(6′allylergoline-8′-β-carboyl) urea-diphospate (FCE 21336). Br J Clin Pharmacol 1987; 1987: 433–8

    Article  Google Scholar 

  16. McArthur RA, Brughera M, Cervini MA, et al. The effects of the D2 agonist cabergoline on MPTP-induced parkinsonism in monkeys. In: Beninger RJ, Palomo T, Archer T, editors. Dopamine disease states: strategies for studying brain disorders. Madrid: CYM, 1996: 67–81

    Google Scholar 

  17. Arai N, Isaji M, Miyata H, et al. Differential effects of three dopamine receptor agonists in MPTP-treated monkeys. J Neural Transm Park Dis Dement Sect 1995; 10(1): 55–62

    Article  PubMed  CAS  Google Scholar 

  18. Fradriksson A, Bassen M, Caccia C, et al. Effects of dopamine agoinists upon locomotor function in denervated mice and rats: comparison with cabergoline. In: Beninger RJ, Palomo T, Archer T, editors. Dopamine disease states: strategies for studying brain disorders. Madrid: CYM, 1996: 181–210

    Google Scholar 

  19. Pianezzola E, Bellotti V, Lacroix R, et al. Determination of cabergoline in plasma and urine by high-performance liquid chromatography with electrochemical detection. J Chromatogr Biomed Appl 1992 Feb 7; 574: 170–4

    Article  CAS  Google Scholar 

  20. Persiani S, Pianezzola E, Broutin F, et al. Radioimmunoassay for the synthetic ergoline derivative cabergoline in biological fluids. J Immunoassay 1992; 13(3): 457–76

    Article  PubMed  CAS  Google Scholar 

  21. Andreotti AC, Pianezzola E, Persiani S, et al. Pharmacokinetics, pharmacodynamics and tolerability of cabergoline, a prolactin-lowering drug after administration of increasing oral doses (0.5,1.0 and 1.5 milligrams) in healthy male volunteers. J Clin Endocrinol Metab 1995; 80: 841–5

    Article  PubMed  CAS  Google Scholar 

  22. Lera G, Vaamonde J, Rodriguez M, et al. Cabergoline in Parkinson’s disease: long-term follow-up. Neurology 1993 Dec; 43: 2587–90

    Article  PubMed  CAS  Google Scholar 

  23. Persiani S, Rocchetti M, Pacciarini MA, et al. The effect of food on cabergoline pharmacokinetics and tolerability in healthy volunteers. Biopharm Drug Dispos 1996; 17: 443–55

    Article  PubMed  CAS  Google Scholar 

  24. Strolin Benedetti M, Dostert P, Dordain G, et al. Cabergoline: metabolism, disposition and lack of pharmacokinetic interaction with selegiline [abstract]. 1st International Meeting Old and New Dopamine Agonists in Parkinson’s Disease: 1993 Dec 12–14; Pisa, Italy

  25. Battaglia R, Strolin Benedetti M, Mantegani S, et al. Disposition and urinary metabolic pattern of cabergoline, a potent dopa-minergic agonist, in rat, monkey and man. Xenobiotica 1993 Dec; 23: 1377–89

    Article  PubMed  CAS  Google Scholar 

  26. Cocchiara G, Strolin Benedetti M. Excretion balance and urinary metabolic pattern of 3H cabergoline in man. Drug Metabol Drug Interact 1992; 10: 199–211

    Article  PubMed  CAS  Google Scholar 

  27. Marsden CD, Parkes JD, Quinn N. Fluctuations in disability in Parkinson’s disease: clinical aspects. In: Marsden CD, Fahn S, editors. Movement disorders. London: Butterworths, 1982: 96–122

    Google Scholar 

  28. Fahn S, Elton RL, Members of the UPDRS Development Committee. Unified Parkinson’s Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, et al., editors. Recent developments in Parkinson’s disease. Vol. 2. Florham Park (NJ): MacMillan Healthcare Information, 1987: 153–63

    Google Scholar 

  29. Jori MC, Franceschi M, Giusti MC, et al. Clinical experience with cabergoline, a new ergoline derivative, in the treatment of Parkinson’s disease. Adv Neurol 1990; 53: 539–43

    PubMed  CAS  Google Scholar 

  30. Ahlskog JE, Muenter MD, Maraganore DM, et al. Fluctuating Parkinson’s disease: treatment with the long-acting dopamine agonist cabergoline. Arch Neurol 1994 Dec; 51: 1236–41

    Article  PubMed  CAS  Google Scholar 

  31. Hutton JT, Morris JL, Brewer MA. Controlled study of the antiparkinsonian activity and tolerability of cabergoline. Neurology 1993 Mar; 43: 613–6

    Article  PubMed  CAS  Google Scholar 

  32. Lieberman A, Imke S, Muenter M, et al. Multicenter study of cabergoline, a long-acting dopamine receptor agonist, in Parkinson’s disease patients with fluctuating responses to levodopa/carbidopa. Neurology 1993 Oct; 43: 1981–4

    Article  PubMed  CAS  Google Scholar 

  33. Yanagisawa N, Kowa H, Mizuno Y, et al. Early phase II study of CG-101 (cabergoline) in Parkinson’s disease [in Japanese]. Rinsho Iyaku 1996; 12(10): 2063–91

    Google Scholar 

  34. Yanagisawa N, Kowa H, Mizuno Y, et al. Clinical evaluation of CG-101 (cabergoline) in patients with Parkinson’s disease: results of late phase II study [in Japanese]. Rinsho Iyaku 1996; 12(17): 3665–718

    Google Scholar 

  35. Ahlskog JE, Wright KF, Muenter MD, et al. Adjunctive cabergoline therapy of Parkinson’s disease: comparison with placebo and assessment of dose responses and duration of effect. Clin Neuropharmacol 1996 Jun; 19: 202–12

    Article  PubMed  CAS  Google Scholar 

  36. Hutton JT, Koller WC, Ahlskog JE, et al. Multicenter, placebocontrolled trial of cabergoline taken once daily in the treatment of Parkinson’s disease. Neurology 1996 Apr; 46: 1062–5

    Article  PubMed  CAS  Google Scholar 

  37. Steiger MJ, El Debas T, Anderson T, et al. Double-blind study of the activity and tolerability of cabergoline versus placebo in parkinsonians with motor fluctuations. J Neurology 1996 Jan; 243: 68–72

    Article  CAS  Google Scholar 

  38. Yanagisawa N, Kowa H, Mizuno Y, et al. Long-term clinical study of CG-101 (cabergoline) in Parkinson’s disease [in Japanese]. Rinsho Iyaku 1996; 12(17): 3799–823

    Google Scholar 

  39. Inzelberg R, Nisipeanu P, Rabey MJ, et al. Long-term tolerability and efficacy of cabergoline, a new long-acting dopamine agonist, in Parkinson’s disease. Mov Disord 1995 Sep; 10: 604–7

    Article  PubMed  CAS  Google Scholar 

  40. Chaudhuri KR, Bhattacharya K, Agapito C, et al. The use of cabergoline in nocturnal Parkinsonian disabilities causing sleep disruption. A comparative study with controlled-release levodopa. Eur Neurol 1999. In press

  41. Yanagisawa N, Kowa H, Mizuno Y, et al. The clinical evaluation of CG-101 (cabergoline) in Parkinson’s disease with combined use of L-DOPA: a multi-centere double-blind comparative study vs. bromocriptine mesilate [in Japanese]. Rinsho Iyaku 1996; 12(17): 3757–98

    Google Scholar 

  42. Inzelberg R, Nisipeanu P, Rabey JM, et al. Double-blind comparison of cabergoline and bromocriptine in Parkinson’s disease patients with motor fluctuations. Neurology 1996 Sep; 47: 785–8

    Article  PubMed  CAS  Google Scholar 

  43. Destee A, Schneider E, Gershanik O, et al. Efficacy and tolerability of cabergoline compared to bromocriptine in patients suffering from levodopa associated motor complications (not on treatment with DA-agents) [abstract]. Mov Disord 1996; 11 Suppl. 1: 269

    Google Scholar 

  44. Chaudhuri KR, Gathani T, Agapito C, et al. Comparative study of the effect of pergolide and cabergoline on nocturnal disabilities in Parkinson’s disease: a single blind study [abstract no. P-TU-081]. Parkinsonism & Related Disorders 1999; 5: S69

    Article  Google Scholar 

  45. Ulm G, Schüler P, MODAC study group. Cabergoline versus pergolide: a video-blinded, randomized, multicenter crossover study. Aktuel Neurol 1999. In press

  46. Rinne UK, Bracco F, Chouza C, et al. Cabergoline in the treatment of early Parkinson’s disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. Neurology 1997 Feb; 48: 363–8

    Article  PubMed  CAS  Google Scholar 

  47. Rinne UK, Bergamasco B, Mamoli A, et al. A five-year double-blind study with cabergoline versus levodopa [abstract]. 13th International Congress on Parkinson’s Disease: 1999 Jul 24–28; Vancouver, Canada

  48. Bhatt MH, Keenan SP, Fleetham JA. Pleuropulmonary disease associated with dopamine agonist therapy. Ann Neurol 1991 Oct; 30: 613–6

    Article  PubMed  CAS  Google Scholar 

  49. Frans E, Dom R, Demedts M. Pleuropulmonary changes during treatment of Parkinson’s disease with a long-acting ergot derivative, cabergoline. Eur Respir J 1992 Feb; 5: 263–5

    PubMed  CAS  Google Scholar 

  50. Ling LH, Ahlskog JE, Munger TM, et al. Constrictive pericarditis and pleuropulmonary disease linked to ergot dopamine agonist therapy for Parkinson’s disease. Mayo Clin Proc 1999; 74: 371–5

    Article  PubMed  CAS  Google Scholar 

  51. Cavallini A, Micieli G, Martignoni E, et al. Cardiopressor effects of short-term treatment with cabergoline in 1-Dopa stable responder parkinsonian patients:relevance of postprandial hypotension. Clin Neuropharmacol 1991 Aug; 14: 343–51

    Article  PubMed  CAS  Google Scholar 

  52. British National Formulary. Cabergoline. London: The Pharmaceutical Press, 1999 Sep: 231

    Google Scholar 

  53. Pharmacia & Upjohn. Cabaser Prescribing Information. Tokyo: Pharmacia & Upjohn, 1999

    Google Scholar 

  54. Olanow CW, Koller WC. An algorithm (decision tree) for the management of Parkinson’s disease: treatment guidelines. Neurology 1998; 50 Suppl. 3: S1–57

    Article  PubMed  CAS  Google Scholar 

  55. Lees AJ, Stern GM. Sustained bromocriptine therapy in previously untreated patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 1981; 44: 1020–3

    Article  PubMed  CAS  Google Scholar 

  56. Gimenez-Roldan S, Tolosa E, Burguera JA, et al. Early combination of bromocriptine and levodopa in Parkinson’s disease: a prospective randomised study of 2 parallel groups over a total follow-up period of 44 months including an initial 8 months double-blind stage. Clin Neuropharmacol 1997; 20: 67–76

    Article  PubMed  CAS  Google Scholar 

  57. Montastruc JL, Rascol O, Sennard JM, et al. A randomised control study of bromocriptine versus levodopa in previously untreated parkinsonian patients: a 3-year follow-up. J Neurol Neurosurg Psychiatry 1989; 52: 773–5

    Article  PubMed  CAS  Google Scholar 

  58. Ahlskog JE. Treatment approaches for early Parkinson’s disease. In: Factor SA, Weiner WJ, editors. Parkinson’s disease at the millenium. New York: Demos Vermande, 2000. In press

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, Private Bag 65901, 41 Centorian Drive, Mairangi Bay, Auckland 10, New Zealand

    Lynda R. Wiseman & Andrew Fitton

Authors
  1. Lynda R. Wiseman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrew Fitton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lynda R. Wiseman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wiseman, L.R., Fitton, A. Cabergoline. CNS Drugs 12, 485–497 (1999). https://doi.org/10.2165/00023210-199912060-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-199912060-00006

Keywords

Search

Navigation